Skip to main content
. 2020 Nov 16;55(6):580–591. doi: 10.1093/abm/kaaa099

Table 1.

Sample characteristics (N = 45)

Mean (SD) or %
Variables Female (n =32) Male (n = 13) Total p
Age (years) 35.88 (10.97) 41.46 (11.33) 37.49 (11.24) .13
Race
 African American 93.8% 100% 95.5% .38
 More than one race 6.3% 0% 4.5%
Hemoglobinopathy genotype .68
 SS 67.7% 69.2% 68.2%
 S-Beta0 thalassemia 6.5% 7.7% 6.8%
 S-Beta+ thalassemia 9.7% 0% 6.8%
 SC 16.1% 23.1% 18.2%
Hemoglobin level 9.27 (1.98) 8.78 (1.86) 9.12 (1.93) .45
White blood cell count 10273.55 (3572.41) 10723.85 (6862.02) 10406.59 (4699.75) .78
Taking hydroxyurea .98
 Yes 31.3% 31.3% 31.1%
Average short-acting opioid use (ME) 23.88 (46.20) 23.56 (33.20) 23.79 (42.48) .98
Average long-acting opioid use (ME) 74.81 (142.51) 38.81 (77.55) 64.43 (127.37) .40
Body mass index (BMI) 27.23 (6.10) 24.64 (6.34) 26.50 (6.20) .22
Education .33
 Some high school 0% 7.7% 2.2%
 High school graduate/GED 15.6% 23.1% 17.8%
 Technical school graduate 12.5% 7.7% 11.1%
 Some college 43.8% 23.1% 37.8%
 College graduate 25.0% 23.1% 24.4%
 Master’s/doctoral degree 3.1% 15.4% 6.6%
Marital status .20
 Married/partnered 25.0% 25.0% 25.0%
 Single 62.5% 50.0% 59.1%
 Divorced/separated 12.5% 25.0% 15.9%

Note. ME, morphine equivalents.